Mineralocorticoid receptor antagonism also confers an additional reduction in albuminuria in patients with CKD already treated with an RAS-inhibitor but may increase the risk of adverse events.41 Thus, future research would be required to elucidate any interactions between vitamin D and both RAAS and SGLT2 blockade in patients with DKD. This evidence concerns the gene NR3C2 and chronic kidney disease.